R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Bringing therapies to patients quicker with integrated CDMO ...

Biotechs and pharmaceutical companies can receive enormous value from a trusted partnership with an integrated CDMO and CRO.

R&D

Unlocking the future of obesity treatment

Obesity is more than a number on the scale, it’s a complex, malignant disease linked to diabetes, cardiovascular conditions, and even certain cancers.

R&D

GLP-1s in CKD: Evidence, market leadership, and key insights...

At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight.

R&D

pharmaphorum podcast Episode 230, Benedict Cross, PhoreMost

Harnessing the cell's own degradation machinery, with Benedi...

Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.

R&D

Future glances: More change, more tech, more harmonisation

According to Deloitte’s 2026 Life Sciences Outlook Survey, the life sciences sector might be becoming increasingly borderless, but only 41% of responding biopharma and medtech executives fe

R&D